Clinical Stage Oncology Co. for Early Cancer Detection
Business Description
Oncology Co. for Early Cancer
The Company is a clinical-stage oncology company with a platform that combines biospectral impedance and AI/ML for point-of-care cancer detection. The lead product delivers rapid, in-procedure assessment of surgical margins—identifying the presence and location of cancer within minutes. Initial commercialization targets skin cancer, where the lead product can shorten procedures, spare healthy tissue, improve surgeon economics, and enhance outcomes. The Company has also built a compelling breast cancer dataset and plans to deploy the lead product to help dramatically reduce the ~20–25% re-surgery (re-excision) rate in partial mastectomies; the breast program is in line for non-dilutive CPRIT support.
The Company has a collaboration with PHC Holdings (formerly Panasonic Healthcare; TSE:6529) to commercialize the lead product. The company anticipates FDA clearance in 2026 and profitability in 2028.
Beyond skin and breast, the Company has generated promising data in lung, pancreatic, esophageal, and colon tissue. Follow-on products include a rapid biopsy-assessment device and a needle-based device leveraging the same platform.
Use of Proceeds: This round will fund FDA clearance activities and the initial commercial launch of the lead product.
NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.
The Company has a collaboration with PHC Holdings (formerly Panasonic Healthcare; TSE:6529) to commercialize the lead product. The company anticipates FDA clearance in 2026 and profitability in 2028.
Beyond skin and breast, the Company has generated promising data in lung, pancreatic, esophageal, and colon tissue. Follow-on products include a rapid biopsy-assessment device and a needle-based device leveraging the same platform.
Use of Proceeds: This round will fund FDA clearance activities and the initial commercial launch of the lead product.
NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.
About the Business
- Years in Operation
- 8
- Facilities & Assets
- Leased
- Market Outlook / Competition
- The Company is well-positioned: offering a technology type (bioelectric / impedance + AI) that is one of the promising directions in margin detection, with some advantages in potential cost, portability, and multi-tissue applicability.
- Opportunities for Growth
- The Company has already taken several concrete steps that are helping it scale / expand. Some of the key ones: strategic partnerships and distribution agreements, approaching product launch timeline as well as development of highly experienced advisors.
About the Sale
- Seller Motivation
- Raise capital to secure FDA clearance and launch.
- Transition Support
- As needed – specific terms for transition support can be negotiated.
- Financing Options
- TBD if structure and terms are acceptable.
Listing Info
- ID
- 2417607
- Listing Views
- 8
Listing ID: 2417607 The information on this listing has been provided by either the seller or a business broker representing the seller. BizQuest has no interest or stake in the sale of this business and has not verified any of the information and assumes no responsibility for its accuracy, veracity, or completeness. See our full Terms of Use. Learn how to avoid scams.
Businesses for SaleIllinois Businesses for SaleIllinois Manufacturing Businesses for SaleIllinois Medical Device Manufacturing Businesses for Sale
Similar Listings
